- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Avoidance behavior.
Displaying page 1 of 1.
EudraCT Number: 2010-019712-20 | Sponsor Protocol Number: DCSP1 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Oslo, Institute of Clinical Dentistry | ||
Full Title: D-CYCLOSERINE ENHANCEMENT OF EXPOSURE TREATMENT OF DENTALLY FEARFUL AND AVOIDANT CHILDREN. A PILOT STUDY | ||
Medical condition: Avoidance of dental care because of dental anxiety often result in reduced dental health and need for sedation or treatment in general anesthesia. Treatment of dental anxiety is time consuming and ... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002379-40 | Sponsor Protocol Number: CAFQ056B2278 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002542-33 | Sponsor Protocol Number: ZYN2-CL-033 | Start Date*: 2022-02-22 | |||||||||||
Sponsor Name:Zynerba Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro... | |||||||||||||
Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004349-42 | Sponsor Protocol Number: NP27936 | Start Date*: 2012-07-16 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | |||||||||||||
Medical condition: Fragile X Syndrome (FXS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) ES (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2008-001766-90 | Sponsor Protocol Number: LuAA21004_311 | Start Date*: 2009-04-09 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxie... | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001581-91 | Sponsor Protocol Number: LuAA21004_301 | Start Date*: 2008-07-21 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) LT (Completed) FR (Completed) NL (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013667-19 | Sponsor Protocol Number: CAFQ056A2212 | Start Date*: 2010-11-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002581-51 | Sponsor Protocol Number: AK002-006 | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:Allakos Inc. | |||||||||||||
Full Title: An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria | |||||||||||||
Medical condition: Patients with different types of chronic urticaria resistant to standard dose antihistamines | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001580-11 | Sponsor Protocol Number: LuAA21004_305 | Start Date*: 2009-04-09 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) NL (Completed) LV (Completed) LT (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000060-42 | Sponsor Protocol Number: D1001066 | Start Date*: 2017-03-15 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001989-15 | Sponsor Protocol Number: TV48125-MH-40142 | Start Date*: 2020-03-27 | ||||||||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of... | ||||||||||||||||||
Medical condition: Migraine and major depressive disorder (MDD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) FI (Completed) GR (Completed) ES (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002369-14 | Sponsor Protocol Number: CHUB-Psy-PAThforsAUD | Start Date*: 2023-07-20 | |||||||||||
Sponsor Name:CHU Brugmann | |||||||||||||
Full Title: Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms. | |||||||||||||
Medical condition: Severe Alcohol Use Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
